Mizuma Takashi, Nakamura Maya, Ina Hiroji, Miyazaki Toshio, Hayashi Masahiro
Department of Drug Absorption and Pharmacokinetics, School of Pharmacy, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Biochim Biophys Acta. 2005 Mar 11;1722(2):218-23. doi: 10.1016/j.bbagen.2004.12.011. Epub 2005 Jan 5.
The intestinal absorption of benzyl beta-glucoside (BNZ beta glc) contained in the fruit of Prunus mume SIEB. et ZUCC. (Rosaceae), which is traditionally used as a medicinal food in Japan, was studied in rat intestines. BNZ beta glc was absorbed from the mucosal to serosal sides. Its metabolite, benzyl alcohol (BAL), was also detected on both the mucosal and serosal sides. In the presence of phloridzin (Na(+)/glucose cotransporter (SGLT1) inhibitor) or in the absence of Na+ (driving force), BNZ beta glc absorption was significantly decreased. Transport clearance of BNZ beta glc across the brush border membrane decreased as its concentration increased. These results indicate that BNZ beta glc is transported by SGLT1. Metabolic clearance of BNZ beta glc also decreased as its concentration increased. The amount ratio of BNZ beta glc to BAL on the serosal side increased with the increase of BNZ beta glc concentration. The intestinal availability of BNZ beta glc was lower in the absence of Na+ than in the presence of Na+, indicating that the SGLT1-mediated transport of BNZ beta glc increases intestinal availability by decreasing the intestinal extraction ratio. This neutraceutical study concluded that intestinal carrier-mediated transport across the brush border membrane improves the intestinal availability of nutritionally, pharmacologically or physiologically active compounds that undergo intestinal metabolism (first-pass effect).
对传统上在日本用作药用食品的蔷薇科植物梅(Prunus mume SIEB. et ZUCC.)果实中所含的苄基β-葡萄糖苷(BNZβglc)在大鼠肠道中的吸收情况进行了研究。BNZβglc从黏膜侧吸收至浆膜侧。在黏膜侧和浆膜侧均检测到其代谢产物苄醇(BAL)。在根皮苷(钠/葡萄糖共转运体(SGLT1)抑制剂)存在的情况下或在无钠(驱动力)的情况下,BNZβglc的吸收显著降低。随着BNZβglc浓度的增加,其跨刷状缘膜的转运清除率降低。这些结果表明,BNZβglc是由SGLT1转运的。随着BNZβglc浓度的增加,其代谢清除率也降低。浆膜侧BNZβglc与BAL的量比随着BNZβglc浓度的增加而增加。在无钠的情况下,BNZβglc的肠道可利用性低于有钠的情况,这表明SGLT1介导的BNZβglc转运通过降低肠道提取率提高了肠道可利用性。这项营养保健品研究得出结论,跨刷状缘膜的肠道载体介导转运提高了经历肠道代谢(首过效应)的营养、药理或生理活性化合物的肠道可利用性。